Literature DB >> 15830715

Immunohistochemical expression of Bax and Bcl-2 in penile carcinoma.

Sadia Saeed1, Connie A Keehn, Farah K Khalil, Michael B Morgan.   

Abstract

There is a complex interplay between the pro-apoptotic Bax and anti-apoptotic Bcl-2 family of proteins and the tumor suppressor gene p53. The pathogenic role of Bax and Bcl-2 protein expression in penile carcinomas has not previously been investigated. We examined Bax and Bcl-2 expression in verrucous (VC) and squamous cell carcinoma (SCC) of the penis. Herein we also present a concise review of p53, Bcl-2/Bax ratios, and their relationship to apoptosis. Fourteen cases of penile carcinoma, including 7 VC and 7 well-differentiated SCC, were analyzed for Bax and Bcl-2 expression by immunohistochemical analysis of paraffin embedded archived tissues. The number of positively staining tumor cells was enumerated per 100 tumor cells within non-overlapping high power fields. The Bax immunoreactivity was similar in VC (19+/-3%) and well-differentiated SCC (15+/-4%) (p = 0.69). The expression of Bcl-2 protein was significantly higher in well-differentiated SCC (69+/-12%) compared to VC (36+/-14%) (p = 0.04). The mean Bcl-2/Bax ratio was significantly lower in VC (1.89) compared to well-differentiated SCC (4.6) (p = 0.05). These findings indicate that penile VC and SCC are immunophenotypically distinct. Bax expression is comparable in verrucous and low-grade squamous cell carcinomas, but Bcl-2 expression of Bcl-2 is significantly higher in the squamous cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15830715

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  6 in total

1.  The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro.

Authors:  Ling Zhang; Jun Gao; Lei Li; Zhaoshen Li; Yiqi Du; Yanfang Gong
Journal:  Mol Biol Rep       Date:  2010-12-16       Impact factor: 2.316

2.  Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.

Authors:  Li Yan Khor; Jennifer Moughan; Tahseen Al-Saleem; Elizabeth H Hammond; Varagur Venkatesan; Seth A Rosenthal; Mark A Ritter; Howard M Sandler; Gerald E Hanks; William U Shipley; Alan Pollack
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

Review 3.  [Value of targeted therapy for penile cancer].

Authors:  A Heidenreich; D Thüer; D Pfister
Journal:  Urologe A       Date:  2008-10       Impact factor: 0.639

Review 4.  Molecular research in penile cancer-lessons learned from the past and bright horizons of the future?

Authors:  Chris Protzel; Philippe E Spiess
Journal:  Int J Mol Sci       Date:  2013-09-26       Impact factor: 5.923

5.  Optimal treatment for penile verrucous carcinoma: a systematic literature review.

Authors:  Dong In Jo; Song Hyun Han; Soon Heum Kim; Hye Young Kim; Hong Chung; Hong Sup Kim
Journal:  BMC Urol       Date:  2021-01-29       Impact factor: 2.264

Review 6.  Understanding genomics and the immune environment of penile cancer to improve therapy.

Authors:  Ahmet Murat Aydin; Jad Chahoud; Jacob J Adashek; Mounsif Azizi; Anthony Magliocco; Jeffrey S Ross; Andrea Necchi; Philippe E Spiess
Journal:  Nat Rev Urol       Date:  2020-08-18       Impact factor: 14.432

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.